134 related articles for article (PubMed ID: 7273267)
1. Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.
Christophidis N; Louis WJ; Lucas I; Moon W; Vajda FJ
Cancer Chemother Pharmacol; 1981; 6(1):59-64. PubMed ID: 7273267
[TBL] [Abstract][Full Text] [Related]
2. Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children.
Winograd B; Lippens RJ; Oosterbaan MJ; Dirks MJ; Vree TB; van der Kleijn E
Eur J Clin Pharmacol; 1986; 30(2):231-8. PubMed ID: 3709652
[TBL] [Abstract][Full Text] [Related]
3. Theoretically required urinary flow during high-dose methotrexate infusion.
Sasaki K; Tanaka J; Fujimoto T
Cancer Chemother Pharmacol; 1984; 13(1):9-13. PubMed ID: 6733846
[TBL] [Abstract][Full Text] [Related]
4. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy.
Slørdal L; Kolmannskog S; Prytz PS; Moe PJ; Aarbakke J
Pediatr Hematol Oncol; 1986; 3(2):127-34. PubMed ID: 3153222
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
8. Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion.
Chen ML; Chiou WL
J Pharmacokinet Biopharm; 1983 Oct; 11(5):515-27. PubMed ID: 6668557
[TBL] [Abstract][Full Text] [Related]
9. [Renal excretion of methotrexate in an in vivo model in minipigs].
Cermanová J; Chládek J; Sispera L; Martínková J
Acta Medica (Hradec Kralove) Suppl; 2000; 43(2):139-47. PubMed ID: 11413676
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
Breithaupt H; Küenzlen E
Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.
Borsi JD; Schuler D; Moe PJ
Cancer Chemother Pharmacol; 1988; 22(1):33-5. PubMed ID: 3260832
[TBL] [Abstract][Full Text] [Related]
12. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
Chan BS; Dawson AH; Buckley NA
Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
[TBL] [Abstract][Full Text] [Related]
13. Effect of urine pH and flow on renal clearance of methotrexate.
Sand TE; Jacobsen S
Eur J Clin Pharmacol; 1981; 19(6):453-6. PubMed ID: 7250179
[TBL] [Abstract][Full Text] [Related]
14. Urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate.
Goren MP; Wright RK; Horowitz ME; Crom WR; Meyer WH
J Clin Oncol; 1987 May; 5(5):804-10. PubMed ID: 3471866
[TBL] [Abstract][Full Text] [Related]
15. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
17. [Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate].
Wiland P; Wiela-Hojeńska A; Swierkot J; Hurkacz M; Orzechowska-Juzwenko K; Szechiński J
Pol Arch Med Wewn; 2003 Aug; 110(2):855-62. PubMed ID: 14682224
[TBL] [Abstract][Full Text] [Related]
18. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.
Iven H; Brasch H; Engster J
Cancer Chemother Pharmacol; 1985; 15(2):115-20. PubMed ID: 4017160
[TBL] [Abstract][Full Text] [Related]
20. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
